Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round 
Aluminum Prices Surge Toward Four-Year Highs After Gulf Smelter Strikes 
Bank of Japan Signals Rate Flexibility Amid Yen Volatility 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
WTO Digital Trade Talks Stall as E-Commerce Tariff Deadline Looms 
Asian Currencies Hold Steady Amid U.S.-Israel-Iran Tensions and BOJ Signals 
Gold Prices Rise Amid Geopolitical Tensions and Safe Haven Demand 
Asian Stocks Rebound as Trump Delays Iran Strike Deadline 
Oil Prices Slip as Trump Extends Iran Ceasefire Deadline Amid Ongoing War Fears 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Goldman Sachs Sees Value in European Real Estate Stocks Despite Sharp Selloff 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Henkel in Advanced Talks to Acquire Olaplex at $2 Per Share 
South Korea March Exports Expected to Surge to Near Five-Year High Amid AI-Driven Chip Demand 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Bristol Myers and AbbVie are reportedly planning to terminate some of their staff in California. The job cuts will be the latest in a string of layoffs in the biopharma industry in the United States.
As per Reuters, a combined total of 360 job roles are set to be affected by the plan. Both Bristol Myers Squibb Co, and AbbVie Inc. reportedly informed the officials of the California administration that they will eliminate some of their employees.
The notices were said to have been filed last week with the state but were only made public a few days after. In the filing, Bristol Myers Squibb indicated that it will remove up to 261 jobs in its offices in two locations in San Diego, California. As of AbbVie, it told the state it will be slashing some 99 jobs in Irvine.
The company’s spokesman said that the layoffs at Bristol Myers are taking place after the company acquired Turning Point Therapeutics Inc. for $4.1 billion. The biopharma’s acquisition deal with the San Diego-based biotech drug developer closed just last month.
Fierce Pharma reported that the job cut notices were separately filed by Bristol Myers and AbbVie under the Worker Adjustment and Retraining Notification (WARN) alerts. The filing is to officially inform California that there will be layoffs from their companies this November.
With the move, Bristol Myers and AbbVie have joined other major biopharmaceutical firms such as Novartis and Biogen in the reduction of their workforce. At any rate, BMS’s job cuts are related to its latest acquisition deal of Turning Point Therapeutics and this was confirmed by the company through its spokesman.
“We are very pleased to have completed the acquisition of Turning Point Therapeutics to further strengthen our leading oncology franchise,” the company said in a separate statement. “As part of the integration, all incoming employees received retention packages tied to continued service to BMS for a period of time and have been encouraged to apply to long-term roles at BMS after their retention period ends.”
Meanwhile, AbbVie was not able to respond immediately to a request for comment regarding the job cuts.
